Mounjaro (Tirzepatide)

Tirzepatide, the active ingredient in Mounjaro, is a dual GIP/GLP‑1 receptor agonist presented as an injectable solution for subcutaneous use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control and support weight management.

GNH USA supplies Mounjaro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing cold‑chain logistics for this biologic product.

Mounjaro is a dual GIP/GLP‑1 receptor agonist used in the treatment of type 2 diabetes mellitus, acting on glucose regulation pathways.

- Type 2 diabetes mellitus: improves blood glucose control, reduces HbA1c levels and may contribute to weight loss.

Mounjaro may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Constipation - Decreased appetite - Abdominal discomfort

Serious or Rare Side Effects: - Acute pancreatitis - Severe hypersensitivity reactions - Diabetic ketoacidosis (especially with insulin deficiency) - Gallbladder disease (cholelithiasis or cholecystitis) - Marked hypoglycaemia when combined with insulin or sulfonylureas

Before initiating therapy, clinicians should consider several safety aspects.

- Monitor blood glucose: adjust concomitant antidiabetic agents to avoid hypoglycaemia. - Assess renal function: use with caution in patients with severe renal impairment. - Evaluate gastrointestinal tolerance: nausea or vomiting may affect adherence. - Review cardiovascular risk: be vigilant for signs of pancreatitis. - Pregnancy and lactation: avoid unless potential benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tirzepatide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Other GLP‑1 receptor agonists: additive gastrointestinal adverse effects. - Medications that cause hypoglycaemia: may potentiate low blood sugar.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Thiazolidinediones: potential for fluid retention and heart failure. - Oral contraceptives: may experience altered absorption or efficacy.